📍 Delhi | 22nd March 2025 | Saturday / 🕕 5:59 PM - 9:01 PM (Entry from 5:30 PM onwards)

1800 890 4317

profitfromit1@gmail.com

📢 Divis Laboratories Q3 FY25 & 9M FY25 Results - 📊💡

Lesson 81/97 | Study Time: 10 Min

Course: Quarterly Result Updates & Analysis

📌 Key Highlights

1️⃣ Financial Performance 📊

🔹 Particulars	📅 Q3 FY25	📅 Q3 FY24	🔥 YoY Growth	📅 9M FY25	📅 9M FY24	🚀 YoY Growth
💰 Revenue (₹ Cr)	2319	1855	+25% 🚀	6775	5542	+22.3% 📊
💼 PBT (₹ Cr)	726	489	+48.5% 🚀	2052	1450	+41.5%
🏆 PAT (₹ Cr)	589	358	+64.5% 🔥	1529	1062	+43.9%

2️⃣ Margin Analysis 📊💰

🔹 Margin Type	Q3 FY25	Q3 FY24	🚀 Change	9M FY25	9M FY24	📈 Change
🔹 Gross Margin %	55.9%	57.2%	📉 -1.3%	57.3%	57.9%	📉 -0.6%
💼 EBITDA Margin %	34.2%	30.5%	📈 +3.7%	32.1%	28.3%	📈 +3.8%
🏆 PAT Margin %	25.4%	19.3%	📈 +6.1%	22.6%	18.5%	📈 +4.1%

3️⃣ Profitability, Solvency, & Liquidity Analysis 💰📊

📊 Ratio	🔥 Q3 FY25	🚀 Q3 FY24	📊 9M FY25	📈 9M FY24
🏆 Return on Equity (RoE) %	15.3%	12.1%	14.8%	11.5%
💼 Return on Assets (RoA) %	10.2%	8.3%	9.7%	8.0%
📊 Return on Capital Employed (RoCE) %	18.4%	14.8%	17.9%	14.5%

Ratio	🔹 Value
💰 Debt-to-Equity Ratio	0.02x (Extremely Low Debt) ✅
🏦 Current Ratio	2.85x (Strong Liquidity) 💰
📊 Interest Coverage Ratio	75x (Very High) 🚀

4️⃣ Valuation Analysis 💰 CMP ₹5,889 & Trail EPS of 77.85

🔹 Metric	📊 Value	📈 Industry Average	⚠️ Verdict
💰 P/E Ratio	76.4x	35-38x	Slightly Overvalued ⚠️
📊 EV/EBITDA	28.1x	25x	Premium Valuation ⚠️
🏆 Price-to-Book	8.5x	7.2x	Expensive 🔥

5️⃣ Outlook - Short & Long Term 📆

6️⃣ Final Verdict 🎯

🔹 Investment View:
📍 Near-term traders: Hold, watch valuation risks ⚠️
📍 Long-term investors: Attractive for consistent returns in pharma sector 💼💊

Previous Lesson Next Lesson

Product Designer

📢 5 STEPS TOWARDS WEALTH 🚀 The Indian Stock Market Way

📢 Divis Laboratories Q3 FY25 & 9M FY25 Results - 📊💡

📢 Divis Laboratories Q3 FY25 & 9M FY25 Results - 📊💡

📌 Key Highlights

✅ Revenue Growth: Strong YoY growth in both Q3 FY25 & 9M FY25 📈 ✅ Profitability: Higher PAT Margins & EBITDA Expansion 💰 ✅ Capex Update: Kakinada Project (Unit-III) started operations from Jan 1, 2025 🏭 ✅ Valuation: CMP ₹5,889 – Trading at a premium valuation 📊

1️⃣ Financial Performance 📊

📈 Consolidated Sales & Profit Growth

🔹 Particulars

📅 Q3 FY25

📅 Q3 FY24

🔥 YoY Growth

📅 9M FY25

📅 9M FY24

🚀 YoY Growth

💰 Revenue (₹ Cr)

2319

1855

+25% 🚀

6775

5542

+22.3% 📊

💼 PBT (₹ Cr)

726

489

+48.5% 🚀

2052

1450

+41.5%

🏆 PAT (₹ Cr)

589

358

+64.5% 🔥

1529

1062

+43.9%

2️⃣ Margin Analysis 📊💰

🔹 Margin Type

Q3 FY25

Q3 FY24

🚀 Change

9M FY25

9M FY24

📈 Change

🔹 Gross Margin %

55.9%

57.2%

📉 -1.3%

57.3%

57.9%

📉 -0.6%

💼 EBITDA Margin %

34.2%

30.5%

📈 +3.7%

32.1%

28.3%

📈 +3.8%

🏆 PAT Margin %

25.4%

19.3%

📈 +6.1%

22.6%

18.5%

📈 +4.1%

📌 Higher EBITDA & PAT Margins indicate efficiency improvements & cost control ✅ 📌 Slight dip in Gross Margin due to raw material costs ⚠️

3️⃣ Profitability, Solvency, & Liquidity Analysis 💰📊

📈 Profitability Ratios

📊 Ratio

🔥 Q3 FY25

🚀 Q3 FY24

📊 9M FY25

📈 9M FY24

🏆 Return on Equity (RoE) %

15.3%

12.1%

14.8%

11.5%

💼 Return on Assets (RoA) %

10.2%

8.3%

✅ Revenue Growth: Strong YoY growth in both Q3 FY25 & 9M FY25 📈
✅ Profitability: Higher PAT Margins & EBITDA Expansion 💰
✅ Capex Update: Kakinada Project (Unit-III) started operations from Jan 1, 2025 🏭
✅ Valuation: CMP ₹5,889 – Trading at a premium valuation 📊

📌 Higher EBITDA & PAT Margins indicate efficiency improvements & cost control ✅
📌 Slight dip in Gross Margin due to raw material costs ⚠️

✅ Revenue Growth Momentum Continues 🚀
✅ Margin Expansion Likely 💰
✅ Capacity Expansion (Kakinada) to Add Further Growth 🏭
⚠️ Risks: Currency fluctuations & raw material price volatility 🌍💰

✅ Strong API & Nutraceuticals Demand 📈
✅ Ongoing Expansion to Boost Production Capacity 🏭
✅ Robust R&D for Future Growth 🧪🔬

📢 Exceptional Q3 & 9M FY25 results with strong profitability & growth. ✅
💰 Low debt, strong liquidity & margin expansion make it financially stable. 📊🏆
📈 Premium valuation reflects high growth potential but caution needed at CMP ₹5,889. 🚀